



For your treatment with TZIELD

Choosing an infusion location

What is TZIELD?

TZIELD is a prescription medicine used to delay the onset of Stage 3 type 1 diabetes, which is when your body can't make enough insulin on its own and may require insulin injections. TZIELD is for adults and children 8 years of age and older who have Stage 2 type 1 diabetes. This means that they have tested positive for 2 or more type 1 diabetes-related autoantibodies, have abnormal blood sugar levels, and do not have type 2 diabetes. It is not known if TZIELD is safe and effective in

How is TZIELD given?



TZIELD is an intravenous (IV) infusion. This means it's given through a needle into a vein in your arm



Infusions are given once a day, every day for 14 days in a row



Each infusion is at least 30 minutes long; however, plan for additional time before and after infusion for preparation and monitoring

Where will TZIELD be given?

children under 8 years of age.

There are 3 site of care options that may be available to you for your TZIELD infusions. You and your doctor can determine which location is best for you based on your insurance coverage and other preferences.

What are my options?	Where do I get infused?	What should I consider when choosing?	How do I get the medication?
Infusion Center or Doctor's Office	All 14 doses of TZIELD are given in an infusion center or doctor's office	Given in a controlled healthcare setting, with infusions and lab draws usually completed in one place; requires transportation or hotel accommodations nearby	TZIELD is sent to the infusion center or your doctor's office
Home Infusion	All 14 doses of TZIELD are given at home by a nurse	Convenient for patients with transportation or work/school challenges; doctors have the ability to monitor remotely	TZIELD is sent to you at home
+ (a) Hybrid of Both	The 14 doses are split, with initial doses given in an infusion center or doctor's office, followed by the remainder given at home by a nurse	Combines doctor oversight when treatment begins and early dose monitoring with convenience of home infusion	Some TZIELD is sent to the infusion center or your doctor's office AND Some TZIELD is sent to you at home

Please see Important Safety Information on next page and <u>Medication Guide</u> and <u>Prescribing Information</u>. Talk to your doctor about TZIELD.

Guiding you through the TZIELD treatment experience

TZIELD COMPASS is a patient support program created to assist you throughout treatment from start to finish and help make your experience as smooth as possible.



Learn more about how you can receive personalized support, including the TZIELD Copay Program

If you have questions, please call TZIELD COMPASS at **1-844-778-2246**, Monday through Friday from 8:00 AM-8:00 PM ET, or send us an email at **COMPASS@sanofi.com**

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TZIELD?

TZIELD may cause serious side effects. These include:

- Cytokine release syndrome (CRS). Signs and symptoms may start during the first 5 days of TZIELD treatment and could include fever, nausea, feeling tired (fatigue), headache, muscle and joint pain, or increased liver enzymes in your blood. Tell your healthcare provider right away if you develop any signs and symptoms of CRS during treatment with TZIELD
- Decrease in white blood cells. TZIELD may cause
 a decrease in a type of white blood cell called
 lymphocytes. A decrease in white blood cells is a
 serious, but common side effect that can affect
 your body's ability to fight infections. A decrease in
 white blood cell counts can happen after your first
 dose. Your white blood cell counts will start to go
 back to normal after your fifth dose of TZIELD. Some
 people may develop longer and more severe
 decreases in lymphocytes

Your healthcare provider will do blood tests to check your liver and your complete blood counts before you start treatment and during treatment with TZIELD. During and after your treatment with TZIELD, your healthcare provider will check for serious side effects, as well as other side effects, and treat you as needed. Your healthcare provider may temporarily or completely stop your treatment with TZIELD, if you develop liver problems, have a serious infection, or if your blood counts stay too low.

What should I tell my healthcare provider before receiving TZIELD?

Before or after receiving TZIELD, tell your healthcare provider about all your medical conditions, including if you:

- have a serious infection or an infection that does not go away or keeps coming back
- have recently received or are scheduled to receive an immunization (vaccine). TZIELD may affect how well a vaccine works. Tell your doctor that you are receiving TZIELD before receiving a vaccine
- are pregnant or plan to become pregnant. TZIELD may harm your unborn baby. Do not receive TZIELD during pregnancy and at least 30 days before a planned pregnancy
- are breastfeeding or plan to breastfeed. It is not known if TZIELD passes into your breast milk and if it can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you receive TZIELD

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of TZIELD?

The most common side effects of TZIELD include:

- rash
- leukopenia (decrease in white blood cell counts)
- headache

These are not all of the possible side effects of TZIELD. Talk to your healthcare provider for more information, and tell them about any side effects you notice. You may report side effects to the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see <u>Medication Guide</u> and <u>Prescribing</u> <u>Information</u>. Talk to your doctor about TZIELD.

TZIELD COMPASS is a patient support program that helps eligible patients gain access to TZIELD and provides them with education and resources related to TZIELD.

TZIELD is the registered trademark of the Sanofi Group.
TZIELD is manufactured by Provention Bio, a Sanofi Company.
© 2025 Sanofi. All rights reserved. MAT-US-2408208-v20-03/2025



